Inhibitory Effects of Macelignan on Tau Phosphorylation and Aβ Aggregation in the Cell Model of Alzheimer's Disease.

Show simple item record

dc.contributor.author Gu, Liang
dc.contributor.author Cai, Nan
dc.contributor.author Li, Meiting
dc.contributor.author Bi, Decheng
dc.contributor.author Yao, Lijun
dc.contributor.author Fang, Weishan
dc.contributor.author Wu, Yan
dc.contributor.author Hu, Zhangli
dc.contributor.author Liu, Qiong
dc.contributor.author Lin, Zhijian
dc.contributor.author Lu, Jun
dc.contributor.author Xu, Xu
dc.coverage.spatial Switzerland
dc.date.accessioned 2023-02-19T23:15:46Z
dc.date.available 2023-02-19T23:15:46Z
dc.date.issued 2022-01
dc.identifier.citation (2022). Frontiers in Nutrition, 9, 892558-.
dc.identifier.issn 2296-861X
dc.identifier.uri https://hdl.handle.net/2292/62940
dc.description.abstract Alzheimer's disease (AD) is a neurodegenerative disorder mainly affecting old population. In this study, two Tau overexpressing cell lines (SH-SY5Y/Tau and HEK293/Tau), N2a/SweAPP cell line, and 3× Transgene (APPswe/PS1M146V/TauP301L) mouse primary nerve cell lines were used as AD models to study the activity and molecular mechanism of macelignan, a natural compound extracted from <i>Myristica fragrans</i>, against AD. Our study showed that macelignan could reduce the phosphorylation of Tau at Thr 231 site, Ser 396 site, and Ser 404 site in two overexpressing Tau cell lines. It also could decrease the phosphorylation of Tau at Ser 404 site in mouse primary neural cells. Further investigation of its mechanism found that macelignan could reduce the phosphorylation of Tau by increasing the level of autophagy and enhancing PP2A activity in Tau overexpressing cells. Additionally, macelignan could activate the PERK/eIF2α signaling pathway to reduce BACE1 translation, which further inhibits the cleavage of APP and ultimately suppresses Aβ deposition in N2a/SweAPP cells. Taken together, our results indicate that macelignan has the potential to be developed as a treatment for AD.
dc.format.medium Electronic-eCollection
dc.language eng
dc.publisher Frontiers
dc.relation.ispartofseries Frontiers in nutrition
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.subject AMPK pathway
dc.subject Alzheimer's disease
dc.subject PERK/eIF2α pathway
dc.subject autophagy
dc.subject macelignan
dc.subject Brain Disorders
dc.subject Dementia
dc.subject Neurosciences
dc.subject Neurodegenerative
dc.subject Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
dc.subject Aging
dc.subject Acquired Cognitive Impairment
dc.subject 2.1 Biological and endogenous factors
dc.subject 2 Aetiology
dc.subject Neurological
dc.subject 1001 Agricultural Biotechnology
dc.subject 1111 Nutrition and Dietetics
dc.title Inhibitory Effects of Macelignan on Tau Phosphorylation and Aβ Aggregation in the Cell Model of Alzheimer's Disease.
dc.type Journal Article
dc.identifier.doi 10.3389/fnut.2022.892558
pubs.begin-page 892558
pubs.volume 9
dc.date.updated 2023-01-21T22:39:11Z
dc.rights.holder Copyright: The authors en
dc.identifier.pmid 35662922 (pubmed)
pubs.author-url https://www.ncbi.nlm.nih.gov/pubmed/35662922
pubs.publication-status Published
dc.rights.accessrights http://purl.org/eprint/accessRights/OpenAccess en
pubs.subtype research-article
pubs.subtype Journal Article
pubs.elements-id 910867
pubs.org-id Bioengineering Institute
dc.identifier.eissn 2296-861X
pubs.record-created-at-source-date 2023-01-22
pubs.online-publication-date 2022-05-18


Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics